JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2019-05-17
• Target enrollment: 0
• Participant gender: All

Summary

The Purpose of this trial is:

• to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL

• to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne

Criteria

Inclusion Criteria:

• relapsed or refractory HL

• ECOG <= 2,

• no major organ dysfunction

• written informed consent

Exclusion Criteria:

• history of another primary malignancy ≤ 2 years

• female patients who are pregnant or breast feeding

• patients with a known history of HIV seropositivity

• chronic active hepatitis